Table 3.
Treatment-related AEs by Preferred Term in ≥2 Patients: Telaglenastat + Cabozantinib
| MedDRA Preferred Term, n (%) | Telaglenastat + Cabozantinib (n=13) | |
|---|---|---|
| All Grades | Grade ≥3 | |
| Patients with ≥1 treatment-related AE | 13 (100) | 4 (31) |
| Diarrhea | 8 (62) | 1 (8) |
| Decreased appetite | 6 (46) | 0 |
| Increased transaminasesa | 6 (46) | 0 |
| Fatigue | 5 (38) | 0 |
| Nausea | 4 (31) | 0 |
| Rash | 4 (31) | 0 |
| Dehydration | 3 (23) | 0 |
| Mucosal inflammation | 3 (23) | 0 |
| Proteinuria | 3 (23) | 0 |
| Vomiting | 3 (23) | 0 |
| Abdominal pain | 2 (15) | 0 |
| Anemia | 2 (15) | 0 |
| Dysgeusia | 2 (15) | 0 |
| Hypertension | 2 (15) | 1 (8) |
| Muscle spasms | 2 (15) | 0 |
| Palmar-plantar erythrodysesthesia syndrome | 2 (15) | 0 |
| Platelet count decreased | 2 (15) | 1 (8) |
| Pruritus | 2 (15) | 0 |
| Weight decreased | 2 (15) | 1 (8) |
NOTE: Other Grade ≥3 AEs: photophobia (n=1)
Abbreviation: ALT, alanine aminotransferase; AST, aspartate aminotransferase
c
Combined terms: alanine transaminase increased and aspartate transaminase increased